Introduction
It is estimated that care for coronary artery disease (CAD) results in annual direct and indirect costs of around €50 billion within the European Union (1) . A sizable proportion of this expenditure results from procedures used with the sole intention to confirm the diagnosis. Invasive coronary angiography (ICA) is still the gold standard for establishing the presence of CAD. Despite some variations in the diagnostic workflow among international guidelines, most algorithms usually recommend noninvasive ischemia testing (NIST) before referral for ICA in stable patients with infarction, percutaneous coronary intervention, coronary artery bypass surgery or undergoing ICA as routine workup before cardiac noncoronary surgery were excluded, as were patients with indications for emergency or urgent cardiac catheterization (acute coronary syndromes, cardiogenic shock or life-threatening ventricular dysrhythmia). The study protocol conforms to the ethical guidelines of the Declaration of Helsinki.
Patient evaluation
Data on demographic characteristics, classic and nonclassic CAD risk factors [including peripheral artery disease (PAD), chronic obstructive pulmonary disease (COPD), cerebrovascular disease (CVD) and renal dysfunction (chronic kidney disease, CKD)], symptomatic status, type and results of NIST as well as the results of the first ICA performed in the study period were prospectively collected. Symptomatic status was categorized as 1) nonanginal symptoms, 2) atypical chest pain (including dyspnea, fatigue or equivalent) or 3) typical angina. Pretest probability for CAD was retrospectively calculated using an update Diamond-Forrester classification (7) . Intermediate probability was arbitrarily defined as pretest risk between 15% and 85% of ischemic heart disease. The modalities of NIST routinely used were exercise treadmill test (ETT) and stress myocardial singlephoton emission computed tomography (SPECT). Only tests performed before the ICA were considered. The results were categorized as positive, negative or equivocal. Degree of positivity of the NIST results was not considered. Information on left ventricular systolic function (LVSF) was considered whenever available. For patients with more than one LVSF assessment method, the preferred method was nuclear ventriculography, after echocardiography and finally was invasive ventriculography. Normal LVSF was defined as LV ejection fraction >55%. A modified Framingham risk score (FRS) (8) was calculated for nondiabetic individuals on the basis of available clinical data, with a moderate score (i.e., 1 point) imputed for either a history of dyslipidemia or the use of statins and for the presence of hypertension or a history of medication use for the treatment of high blood pressure.
Invasive coronary angiography
Interpretation of ICA was based on visual assessment only. No quantitative coronary angiogram was performed and data from intracoronary imaging, like fractional flow reserve, intravascular ultrasound or optical coherence tomography, were not considered. Obstructive CAD was defined as stenosis ≥50% of the left main coronary artery or stenosis ≥70% of a major epicardial vessel or branch vessel with at least 1.5 mm in diameter. Normal coronary artery was defined as complete absence of any luminal narrowing detectable by angiography. Nonobstructive CAD was defined as CAD not meeting the criteria for obstructive CAD or normal coronary arteries.
Statistical analysis
We determined the rate of obstructive CAD in the overall population and also according to clinical pretest probabilities and results of NIST. In order to identify variables associated with obstructive CAD, the population was divided into two groups, patients with and without obstructive CAD. We compared the baseline demographic characteristics, cardiovascular risk factors, symptoms and results of NIST between the groups. Normally distributed continuous variables were compared using Student's t-tests and are expressed as mean ± SD; continuous variables not normally distributed were compared using Mann-Whitney tests and are expressed as medians and interquartile ranges. Variables that showed association with obstructive CAD in univariate analysis (p<0.10) were included in a multivariate logistic regression model to identify independent correlates (p<0.05).
To study the incremental value of different parameters in predicting obstructive CAD, a stepwise (six steps) logistic regression analysis was carried out, starting with (1) FRS alone and then sequentially adding, (2) nonclassic risk factors, (3) symptomatic status, (4) pretest probability of CAD, (5) LVSF and finally (6) NIST result. The receiver operating characteristic curves of each model were compared using a nonparametric method (9) . A p value of less than 0.05 was considered statistically significant. All data were analyzed using SPSS 16.0.
Results

Study population
The study population consisted of 2,600 patients with suspected CAD who were undergoing their first elective ICA, 13.6% of them without any previous NIST. This final cohort represented 47.6% of a total of 5,458 ICA procedures performed during the 7 years of the study period. Reasons for patients' exclusion were known history of heart disease in 1,590 (29.1%), urgent ICA indication in 1,193 (21.9%) and other reasons such as routine workup based on institutional defined protocols in 75 (1.3%) patients (Fig. 1) .
Prevalence of obstructive CAD
The prevalence of obstructive CAD was 48.8% (n = 1,268). Normal coronary arteries as defined per protocol were found in 1,035 (39.8%) patients and the remaining represents patients with nonobstructive CAD (10.4%). Multivessel disease was present in 735 patients representing 58% of all obstructive CAD and 28.3% of the entire population. Left main and/ or three-vessel disease was present in 323 patients (12.4% of the entire population).
Demographic and clinical characteristics
Detailed population characteristics are described in Table I . In general, the study cohort consisted of a predominantly male population (60%), with a low (5.7%) prevalence of associated comorbidities. Except for COPD and CKD, all traditional and nontraditional cardiovascular risk factors were significantly associated with the presence of obstructive CAD in univariate analysis (Tab. II). One third of the cohort had no anginal symptoms but was sent for ICA due to perceived high risk, high FRS and/or a positive NIST. Most patients (85.1%) were classified in an intermediate clinical pretest probability of ischemic heart disease. Patients with low and high pretest probabilities represented 3.4% and 11.5% of the whole population, respectively. Typical symptoms of angina were present in half the population and were also significantly associated with obstructive CAD. After adjustment however, only severe symptoms (Canadian Cardiovascular Society (CCS) 3 or 4) were independently associated with obstructive CAD (OR 9.1; 95% CI 4.33-19.1).
Noninvasive ischemia test and LVSF
From the 2,600 patients included, the vast majority (86.4%) had at least one NIST prior to ICA. Considering that ischemia testing would be justified only in patients in an intermediate pretest risk category, an NIST was appropriately used in 73.4% of the whole population. ETT was the single test performed in 1,201 (46.2%), SPECT only in 782 (30.1%) and 262 patients (10.1%) had both. Only 2 patients in the low-risk category did not receive a previous NIST. Likelihood of receiving an NIST before ICA was not significantly different in the intermediate and high-risk categories (86.4% vs 82.6%, respectively, p = 0.08). Ninety-three percent of patients had a positive result in at least one NIST. Inconclusive and negative results in one or both tests were found in 5% and 2%, respectively. Rate of obstructive CAD did not differ after a patient has made a SPECT or an ETT (47.2% and 46.3%, respectively, p = 0.68). Also, rate of obstructive CAD did not differ after a positive SPECT or ETT (49.0% and 48.4%, respectively, p = 0.83). Figure 2 shows the rate of obstructive CAD according to pretest likelihood and NIST results. As expected, there was a progressive increase in the rate of obstructive CAD from low to high pretest likelihood. Interestingly though, in the intermediate risk category where an NIST is usually considered necessary, observed rate of obstructive CAD did not differ significantly for those with positive or negative NIST (47% vs 43%, respectively, p = 0.66). Equivalent rates of obstructive CAD were also found in the high pretest risk category, when patients with positive NIST were compared to those with no previous NIST (77.6% vs 78.8%).
For 262 patients ETT and SPECT were used sequentially and both tests resulted positive for ischemia in 47%. The prevalence of obstructive CAD was not significantly different when only one NIST resulted positive versus both positive, 43.4% and 49.4% (p = 0.23).
An assessment of LVSF was available for analysis in 2,170 patients (83.4% of the study population). From these patients, normal LVSF was found in 89% and moderate to severe LV systolic dysfunction was present in 3.3%. Prevalence of obstructive CAD in patients with any degree of LV systolic dysfunction was 70.1%.
Correlates of obstructive CAD
Increasing age, male sex, history of smoke, diabetes, left ventricular dysfunction and severe angina were independent 
Discussion
In this study including 2,600 patients with suspected CAD undergoing their first elective ICA in a single tertiary care, urban and public European center, the rate of obstructive CAD was 48.8%. This occurred despite appropriate use (but not necessarily interpretation) of noninvasive stress tests in more than 70% of the patients.
The incidence of obstructive CAD as diagnosed by ICA in elective patients has been suggested as a health care performance measure (10) and the 2013 catheterization and percutaneous coronary intervention standards from the Accreditation for Cardiovascular Excellence organization suggests this figure should be above 60% (11) . However, strategies to achieve this goal are not simple. Most international guidelines, largely based on prognostic reasons, suggest that patients in pretest intermediate risk category should be selected for ICA according to NIST results (2, 3). However, despite geographic and temporal variations in the rate of no obstructive disease after ICA, most contemporary studies using NIST strategies for patient selection fail to show success in increasing the yield of ICA. Genders et al (7) in a multicenter study involving 11 European hospitals reported a rate of obstructive CAD of 58% (ranging from 39.4% to 75.5%). Patel et al (5) in the USA reported a rate of 37.6% of obstructive CAD among patients who underwent elective ICA in the National Cardiovascular Data Registry. There was however a wide regional variation among the hospital referral regions, from 23% to 100% (12) .
Several factors may influence the diagnostic performance of ICA. The increased availability and more liberal use of ICA may be one explanation. The 30-year-old Coronary Artery Surgery Study (CASS) (13) with more than 20,000 angiograms showed 81% of patients with obstructive CAD. This is in contrast with the more recent data from registries showing that this rate is between 38% and 50% (5, 14) . Even though this may suggest a temporal decrease in ICA yield, it is difficult to draw definite conclusions since past studies included patients with varying cut points to define obstructive CAD, with previous myocardial infarction or revascularization procedures, with urgent indications and failure to report on the used noninvasive ischemia test strategy, if any.
Also, the impact of NIST on the ICA performance is not entirely clear. A recent published study (4) suggests that despite the increasing availability of noninvasive tests through the years, the proportion of patients with normal coronary arteries or undergoing revascularization remains unchanged. One of the often pointed reasons for this is the overall low pretest probability of obstructive CAD in the studied population. In our cohort more than 85% fell in the intermediate risk category and thus an NIST would be considered appropriately indicated. Germane to this discussion is not just the appropriate indication for NIST but also the appropriate interpretation of the results. Notwithstanding the fact that NIST has intrinsic accuracy and referral strategy limitations, there may be several other factors driving use of ICA after NIST. These correlates of obstructive CAD (Tab. III). A positive NIST was associated with obstructive CAD in univariate analysis, but after adjustment this association was no longer significant (OR 1.69; 95% CI 0.952-3.09). The strongest correlate of obstructive CAD was the presence of severe angina (class 3 or 4 of CCS) (OR = 9.1; 95% CI 4.3-19.1), left ventricular systolic dysfunction (OR = 3.3; 95% CI 1.7-6.3) and male sex (OR = 3.04; 95% CI 2.09-4.44).
A stepwise analysis was performed to study the incremental value of different parameters in predicting obstructive CAD (Fig. 3) . Predictive power of each model is given by the C-statistic value over a 95% CI. The first model included only a modified FRS as initial approach for general CV risk assessment irrespective of symptomatic status (0.595, 0.569-0.620). In the second model, nonclassic risk factors and comorbidities such as PAD, CVD, CKD and COPD were added. The C-statistic for this model remained unchanged (0.601, 0.576-0.627). With the incorporation of the symptomatic status there was a significant increase in the model's predictive ability (0.735, 0.712-0.758; p<0.001). When we added the pretest probability (obtained by the Diamond-Forrester method) no change was noted. In the fifth step, inclusion of the LVSF caused a slight, albeit not significant (p = 0.29), increase in the predictive ability (0.751, 0.729-0.773). Finally, the sixth step consisted in the addition of the noninvasive ischemia test results, which (after enrolling 1,078 patients) have found that even for these high-risk patients with core-lab adjudicated moderate to severe ischemia, 13.6% were found to have no obstructive CAD (19) . Even though these findings may represent true flow limitation due to small vessel disease or endothelial dysfunction, it illustrates the thesis that even in an optimal environment, patient selection based on NIST may not be sufficient to increase the diagnostic yield of ICA.
In this study we also sought to determine factors associated with the presence of obstructive CAD as defined by ICA. Demographic and symptom characteristics are generally used to estimate pretest risk of CAD based on clinical risk assessment models (15, 20) . The original populations from which these data were derived as well as the validation cohort data used are now over 30 years old and were obtained before the current wide availability of ICA. Thus, it is acknowledged that risk assessment in these stratification models may be now overestimated at least in the primary care setting (21) . Nonetheless, our data confirm that typical angina was the strongest independent predictive factor for obstructive CAD followed by other traditional risk factors such as older age, male sex, use of tobacco, diabetes, as well as the presence of abnormal LVSF. In fact, in our stepwise construct, the only significant increment in the ability to predict obstructive CAD was observed when symptomatic status was considered (increase in area under the curve (AUC) from 0.60 to 0.74). Moreover, use of NIST did not significantly add predictive power over demography and symptoms, especially when LVSF was also considered (AUC change from 0.73 to 0.74). This remained true irrespective of Framingham baseline risk (data not shown).
These observations suggest that there is room for improvement and better strategies for patient stratification, before undergoing ICA, are desirable. The incremental value of NIST is limited and therefore other methods of functional and/or anatomic assessment to increase the yield of ICA are may include the role of the patients', family and colleagues' expectations, fear of liability and, importantly, a feeling, albeit debatable, that prognostic risk stratification is not complete until the coronary anatomy is known (15, 16) . If we are to take this last factor into account, coronary computed tomography angiography (CCTA) may have an important role (17, 18) . The ongoing ISCHEMIA trial is evaluating the best management strategy for patients with stable ischemic heart disease. Most patients are required to undergo CCTA before randomization both to confirm the presence of obstructive CAD and to exclude left main disease. Preliminary results could determine the incremental value of NIST in confirming CAD diagnosis but we could not determine the overall performance of the NIST, and most notably its ability to exclude CAD. Third, the database was not powered to provide information on details of NIST results. Information such as high-risk features, extent or ischemia location or reason for equivocal results was not available. Fourth, even though data on symptomatic status was prospectively collected at the initial clinical interview, the database is also a clinical tool and thus it is susceptible to posttest symptom reclassification bias. Hence, it is not unlikely that an initially designated typical angina would be reclassified as atypical or absent after an ICA showing normal epicardial coronaries, particularly if symptoms are inconsistent. Fourth, angiographic findings were not adjudicated and lesion severity assessment was based on operator's semiquantitative angiographic classification. Also, we did not correlate ischemic territories with distribution of lesions in the coronary tree. Thus, lack of use of invasive fraction flow reserve in this cohort is a limitation given its demonstrated reclassification potential. Fifth, only ETT and SPECT were used necessary (17, 18, (22) (23) (24) . Finally, in this era of increasing use and even dependence on medical technology our study shows that careful history taking for the accurate elucidation of symptoms, especially typical angina, should not be overlooked in the evaluation of patients with CAD.
Limitations
First, this is a retrospective analysis. It is possible that there might have been variables used by clinicians to direct patients for ICA namely rest ECG abnormalities, nonclassified symptoms or other hidden confounders not reflected in pretest risk estimation or NIST results. Also, FRS may be underestimated because in our database dyslipidemia and hypertension are classified as categorical variables and therefore a modified FRS was used using imputed values for lipid levels and blood pressure. Second, patients were subjected to referral bias. This analysis was focused exclusively in patients referred for ICA. Thus, we have no data on subjects evaluated for presence of CAD that for any reason did not receive ICA. Therefore, we 
